A clinical trial with bilirubin is ongoing at Södersjukhuset at the moment; it is expected to be completed mid-March, as previously disclosed on 28 January. When it is completed, regulatory documentation will be compiled in order to achieve the CE Mark approval.

Calmark already has The Swedish Ethical Review Authority's approval for clinical studies on the Company's other biomarkers, glucose and LDH, as well as an agreement with the children's hospital Sachsska barnsjukhuset, part of Södersjukhuset, to conduct them. These trials are planned to commence during spring.

"It is important for us that the sales launch of our first product, Neo-Bilirubin, is not delayed. This is also the product which we consider to have the most substantial market potential. The development of the Neo-Glucose and Neo-LDH products are progressing, but there is still some work remaining before we can enter the validation and verification stage. Only then can we start the clinical trials. According to the updated plan, we should be able to complete these before the summer holidays," says Anna Söderlund, CEO.

‍

This information is information that Calmark Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 13 February 2020, 16:30 CET.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

‍